APOL1 Genetic Testing in African Americans
NCT05656261
This study is recruiting at 1 US site in 1 state, according to its ClinicalTrials.gov record last updated .
Summary
Recent breakthroughs in medical genetics have discovered that a portion of kidney failure affecting the Black community is mediated by coding variants in a gene called apolipoprotein L1 (APOL1) - and that genetic variants, not race - account for increased risk. For APOL1 genetic testing to be applied in a manner that improves patient care and outcomes, more information is needed regarding associations of genotype with clinical parameters related to kidney health.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Genetic Predisposition
- Chronic Kidney Diseases
- Nephropathy
- APOL1 Associated Kidney Disease
- Disparities
Eligibility basics and study details
- Study type
- Observational
- Phase
- Not applicable
- Ages
- 18 to 90 years
- Sex
- All
- Healthy volunteers
- Accepted
- Sponsor
- St. Louis University
- Last updated on ClinicalTrials.gov
- March 20, 2025
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
Missouri · 1
- SSM Health Saint Louis University Hospital · St Louis, MO
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.